Could a drug help AML patients fight Chemo-Related anemia?
NCT ID NCT07663864
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial investigates whether luspatercept can treat anemia caused by chemotherapy in adults with low-risk acute myeloid leukemia (AML). Participants receive luspatercept injections after chemotherapy, and researchers monitor hemoglobin levels and safety. The study aims to find the best timing for the drug and assess its effectiveness in reducing severe anemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
luspatercept
What this could lead to
If it works, this could offer a new way to manage chemotherapy-induced anemia in AML patients, reducing the need for blood transfusions.
What could go wrong
This is an early-phase, single-arm study with only 40 participants, so results may not be generalizable. The drug may not effectively raise hemoglobin or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCING ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Department of Hematology, Guangdong Second Provincial General Hospital
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••